Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples